Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Nov 28

PMID 36440049

Authors

Chantal Lokhorst

Sjoukje van der Werf

Rolf M F Berger

Johannes M Douwes

Affiliations

Soon will be listed here.

Abstract

Introduction: Currently, risk stratification is the cornerstone of determining treatment strategy for patients with pulmonary arterial hypertension (PAH). Since the 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines for the diagnosis and treatment of pulmonary hypertension recommended risk assessment, the number of studies reporting risk stratification has considerably increased. This systematic review aims to report and compare the variables and prognostic value of the various risk stratification models for outcome prediction in adult and pediatric PAH.

Methods: A systematic search with terms related to PAH, pediatric pulmonary hypertension, and risk stratification was performed through databases PubMed, EMBASE, and Web of Science up to June 8, 2022. Observational studies and clinical trials on risk stratification in adult and pediatric PAH were included, excluding case reports/series, guidelines, and reviews. Risk of bias was assessed using the Prediction model Risk Of Bias Assessment Tool. Data on the variables used in the models and the predictive strength of the models given by c-statistic were extracted from eligible studies.

Results: A total of 74 studies were eligible for inclusion, with this review focusing on model development ( = 21), model validation ( = 13), and model enhancement ( = 9). The variables used most often in current risk stratification models were the non-invasive WHO functional class, 6-minute walk distance and BNP/NT-proBNP, and the invasive mean right atrial pressure, cardiac index and mixed venous oxygen saturation. C-statistics of current risk stratification models range from 0.56 to 0.83 in adults and from 0.69 to 0.78 in children (only two studies available). Risk stratification models focusing solely on echocardiographic parameters or biomarkers have also been reported.

Conclusion: Studies reporting risk stratification in pediatric PAH are scarce. This systematic review provides an overview of current data on risk stratification models and its value for guiding treatment strategies in PAH.

Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022316885], identifier [CRD42022316885].

Citing Articles

Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies.

Reinders S, Didden E, Ong R Respir Res. 2024; 25(1):373.

PMID: 39415261 PMC: 11481430. DOI: 10.1186/s12931-024-02994-w.

Embracing the challenges of neonatal and paediatric pulmonary hypertension.

Ivy D, Rosenzweig E, Abman S, Beghetti M, Bonnet D, Douwes J Eur Respir J. 2024; 64(4).

PMID: 39209483 PMC: 11525338. DOI: 10.1183/13993003.01345-2024.

Editorial: Therapeutics in pulmonary arterial hypertension.

Adao R, Perez-Vizcaino F, Redwan B, Bras-Silva C Front Cardiovasc Med. 2024; 11:1463305.

PMID: 39165259 PMC: 11333342. DOI: 10.3389/fcvm.2024.1463305.

Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.

Lokhorst C, van der Werf S, Berger R, Douwes J J Am Heart Assoc. 2024; 13(13):e034151.

PMID: 38904230 PMC: 11255703. DOI: 10.1161/JAHA.123.034151.

Growing up with Idiopathic Pulmonary Arterial Hypertension: An Arduous Journey.

Dutilleux T, Farhat N, Heying R, Seghaye M, Beghetti M Pediatr Rep. 2023; 15(2):301-310.

PMID: 37218926 PMC: 10204495. DOI: 10.3390/pediatric15020026.

References

Harbaum L, Fuge J, Kamp J, Hennigs J, Simon M, Sinning C . Blood carbon dioxide tension and risk in pulmonary arterial hypertension. Int J Cardiol. 2020; 318:131-137. DOI: 10.1016/j.ijcard.2020.06.069. View

Lewis R, Johns C, Cogliano M, Capener D, Tubman E, Elliot C . Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019; 201(4):458-468. PMC: 7049935. DOI: 10.1164/rccm.201909-1771OC. View

Simpson C, Griffiths M, Yang J, Nies M, Vaidya R, Brandal S . The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension. ERJ Open Res. 2021; 7(4. PMC: 8503279. DOI: 10.1183/23120541.00378-2021. View

DAlonzo G, Barst R, Ayres S, Bergofsky E, Brundage B, Detre K . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5):343-9. DOI: 10.7326/0003-4819-115-5-343. View

Hoeper M, Kramer T, Pan Z, Eichstaedt C, Spiesshoefer J, Benjamin N . Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00740-2017. View

McLaughlin V, Archer S, Badesch D, Barst R, Farber H, Lindner J . ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American.... J Am Coll Cardiol. 2009; 53(17):1573-619. DOI: 10.1016/j.jacc.2009.01.004. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Respir J. 2015; 46(4):903-75. DOI: 10.1183/13993003.01032-2015. View

Kylhammar D, Hjalmarsson C, Hesselstrand R, Jansson K, Kavianipour M, Kjellstrom B . Predicting mortality during long-term follow-up in pulmonary arterial hypertension. ERJ Open Res. 2021; 7(2). PMC: 8165378. DOI: 10.1183/23120541.00837-2020. View

Xanthouli P, Koegler M, Marra A, Benjamin N, Fischer L, Eichstaedt C . Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up. Respir Res. 2020; 21(1):127. PMC: 7245826. DOI: 10.1186/s12931-020-01393-1. View

10.

Chiu S, Weng K, Lin M, Wang J, Hwang B, Dai Z . Congenital heart disease with pulmonary artery hypertension in an Asian cohort-initial report from TACHYON (TAiwan congenital heart disease associated with pulmonarY arterial hypertension) registry. Int J Cardiol. 2020; 317:49-55. DOI: 10.1016/j.ijcard.2020.05.086. View

11.

Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00889-2017. View

12.

Humbert M, Sitbon O, Yaici A, Montani D, OCallaghan D, Jais X . Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010; 36(3):549-55. DOI: 10.1183/09031936.00057010. View

13.

Chang K, Duval S, Badesch D, Bull T, Chakinala M, De Marco T . Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022; 11(9):e024969. PMC: 9238604. DOI: 10.1161/JAHA.121.024969. View

14.

Haddad F, Contrepois K, Amsallem M, Denault A, Bernardo R, Jha A . The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension. Chest. 2021; 161(5):1347-1359. PMC: 9131051. DOI: 10.1016/j.chest.2021.10.045. View

15.

Badagliacca R, Papa S, Manzi G, Miotti C, Luongo F, Sciomer S . Usefulness of Adding Echocardiography of the Right Heart to Risk-Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2020; 13(9):2054-2056. DOI: 10.1016/j.jcmg.2020.04.005. View

16.

Griffiths M, Yang J, Simpson C, Vaidya D, Nies M, Brandal S . ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest. 2021; 160(1):297-306. PMC: 8295908. DOI: 10.1016/j.chest.2021.01.085. View

17.

Hoeper M, Pausch C, Olsson K, Huscher D, Pittrow D, Grunig E . COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2021; 60(1). PMC: 9260123. DOI: 10.1183/13993003.02311-2021. View

18.

Imai R, Adachi S, Yoshida M, Shimokata S, Nakano Y, Okumura N . Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan. Can J Physiol Pharmacol. 2020; 98(9):653-658. DOI: 10.1139/cjpp-2019-0640. View

19.

Austin C, Burger C, Kane G, Safford R, Blackshear J, Ung R . High-risk echocardiographic features predict mortality in pulmonary arterial hypertension. Am Heart J. 2017; 189:167-176. DOI: 10.1016/j.ahj.2017.04.013. View

20.

Hjalmarsson C, Radegran G, Kylhammar D, Rundqvist B, Multing J, Nisell M . Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension. Eur Respir J. 2018; 51(5). DOI: 10.1183/13993003.02310-2017. View